Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 10—October 2022

Endofungal Mycetohabitans rhizoxinica Bacteremia Associated with Rhizopus microsporus Respiratory Tract Infection

Shangxin YangComments to Author , Victoria Anikst, and Paul C. Adamson
Author affiliation: David Geffen School of Medicine at University of California–Los Angeles, Los Angeles, California, USA

Main Article


Antibiotic susceptibility results for Mycetohabitans rhizoxinica isolate from a 65-year-old woman with multiple myeloma undergoing chimeric antigen receptor T-cell therapy admitted to the hospital for worsening foot and ankle pain, California, USA*

Antibiotic MIC, µg/mL*
Amoxicillin/clavulanate ≤2
Ceftriaxone ≤1
Ceftazidime ≤0.5
Ceftolozane/tazobactam ≤0.5
Cefepime ≤0.5
Ceftazidime/avibactam ≤2
Ertapenem ≤0.25
Imipenem ≤1
Meropenem ≤0.25
Piperacillin/tazobactam ≤8
Amikacin 8
Gentamicin ≤1
Tobramycin ≤1
Ciprofloxacin 0.5
Levofloxacin ≤0.5
Trimethoprim/sulfamethoxazole ≤1/20

*Susceptibility testing was performed on broth-microdilution panels prepared in-house in accordance with CLSI guidelines from the Clinical and Laboratory Standards Institute (

Main Article

Page created: September 06, 2022
Page updated: September 21, 2022
Page reviewed: September 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.